NPH Insulin

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

NPH Insulin (brand names Humulin, Novolin) — Antidiabetic; Intermediate-acting insulin.

Identification

• Therapeutic class: Antidiabetic.
• Pharmacologic class: Intermediate-acting insulin.

Pharmacology

• Mechanism of action: Intermediate basal coverage; cloudy suspension.
• Onset / peak / duration: Onset 1 to 2 hours; peak 4 to 12 hours; duration 12 to 18 hours.
• Half-life / therapeutic level: Monitor glucose.

Clinical use

• Indications: Basal or split coverage in type 1 and type 2 diabetes.
• Usual dose, route, frequency: SubQ once or twice daily.
• Maximum dose / adjustments: Individualized.

Safety

• Contraindications: Hypoglycemia, hypersensitivity.
• Black box warning: None.
• Interactions: Same insulin interactions.
• Pregnancy / lactation: Insulin preferred.
• High-alert: Yes.

Adverse effects

• Common side effects: Hypoglycemia (notable peak risk), weight gain.
• Serious effects to report: Severe hypoglycemia, especially during the peak.
• Antidote / reversal: Glucose or glucagon.

Nursing process

• Assessment before administration: Blood glucose, meal timing relative to peak.
• Interventions during therapy: Gently roll to resuspend (do not shake); when mixing with regular, draw clear before cloudy.
• Monitor: Blood glucose, A1c, peak-time lows.
• Evaluation / expected outcome: Intermediate glucose control.

Patient teaching

• Patient teaching: Watch for lows during the peak; eat consistent meals.
• Notify provider if: Frequent lows.
• Administration tips: SubQ; resuspend gently; cloudy appearance is normal.